oral semaglutides Semaglutide, the First Ingestible Glucagon-Like Peptide-1 Receptor Agonist: Could It Be a Magic Bullet for Type 2 Diabetes? Oral Semaglutide Shows Promise in

Brandon Richland, MD Wegovy, the brand name for the medication semaglutide, has gained attention in the realm of weight loss for its effectiveness

Funding Financial support for this project was provided by a special Ministry of Science and Higher Education subsidy to maintain research capacity (grant numbers: K/ZDS/002963 and N41/DBS/000581A

Eur Heart J 1992;13:251-5

Vilazodone and vortioxetine have been approved to treat major depressive disorder, but do not have a large body of evidence supporting their use in anxiety disorders

Heres why this move deserves attention Big Bet on a Blockbuster Segment Entry into the fast-growing GLP-1 (semaglutide) space Taps into a market set to explode with rising diabetes & obesity cases Timed perfectly post patent expiry early-mover advantage Product That Matches Global Standards Once-weekly injectable better patient adherence Available in 2 mg & 4 mg pre-filled pens Backed by Phase III data comparable efficacy + strong safety Premium Generic Strategy (Not a Price WarYet) Priced at ~4,200/month Positioned as a trusted, high-quality branded generic Targets urban, quality-conscious patients over deep discounting Full-Stack Manufacturing Power API + formulation + delivery device all in-house Strong edge in complex peptides & scale-up capability Sets the stage for global expansion Beyond Drug: Building a Patient Ecosystem SemaKare support program Focus on adherence, education & outcomes Shift from product-selling solution-building Competitive Storm Incoming Multiple Indian pharma giants entering semaglutide Likely outcomes: Price erosion Wider access Massive market expansion The Real Play

Cell Division : This vitamin is necessary for proper cell division and growth throughout the body